Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

The survey also found that flexible and virtual appointments, as well as transportation support, were helpful while on ...

ViiV Healthcare, the specialist HIV company majority owned by GSK (LSE: GSK), today announced the presentation of new ...

Cabotegravir – given the trade name Apretude – can be dosed just six times a year and showed superior results to daily, oral therapy with Gilead's widely used Truvada (emtricitabine and ...

ViiV Healthcare sponsored events to address the climbing rates of HIV infections on HBCU campuses and the surrounding Black ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 ...

The announcement marks another important milestone in our efforts to accelerate access to the only long-acting PrEP available ...

Studies from OPERA and Trio cohorts provide further real-world evidence supporting CAB LA for PrEP’s high effectiveness and adherence in preventing HIV acquisition Patient-reported results for CAB LA ...

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...

At least 2 million doses of Apretude will be made available to meet growing demand where unmet need is greatest.

How Was It Studied for the Prevention of HIV? Two large studies were conducted to see if Apretude is safe and effective as a PrEP regimen in people at risk of getting HIV. In both studies ...